Relvar - Managing Asthma and COPD Symptoms

Q: What is Relvar Ellipta?

1. What Relvar Ellipta is and what it is used for Relvar Ellipta contains two active substances: fluticasone furoate and vilanterol. Two different strengths of Relvar Ellipta are available: fluticasone furoate 92 micrograms/vilanterol 22 micrograms and fluticasone furoate 184 micrograms/vilanterol 22 micrograms.

Q: Should I read the patient information leaflet before taking Relvar Ellipta?

Remember to always read the Patient information leaflet before taking Relvar Ellipta. This page is specifically for patients who have been prescribed Relvar Ellipta. If you are not a patient please return to the public website. How it works, what’s in it, how often to take it and other questions about Relvar Ellipta

Q: How effective is Relvar Ellipta?

A fourth study in 1,522 patients showed that Relvar Ellipta was as effective as another medicine containing a corticosteroid (fluticasone propionate) and a long-acting beta-2 agonist (salmeterol). These patients were already well controlled with the comparator medicine and Relvar Ellipta treatment was able to maintain their FEV1.

Relvar is a prescription medication used for the treatment of asthma and chronic obstructive pulmonary disease (COPD). It contains a combination of fluticasone and vilanterol to help control asthma symptoms and improve lung function.

Relvar FAQ

Image credit: rightbreathe.com

What is Relvar Ellipta used for?

Relvar Ellipta is indicated for the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting beta 2 -agonist and inhaled corticosteroid) is appropriate:

What is a Relvar Ellipta inhaler used for?

Relvar ellipta inhaler is used for people with severe COPD who have repeated attacks of breathlessness, despite regular use of long-acting bronchodilators such as formoterol or salmeterol. Only the Relvar ellipta 92/22 micrograms strength inhaler is used for COPD.

Does Relvar Ellipta have side effects?

As for all medicines, data on the use of Relvar Ellipta are continuously monitored. Side effects reported with Relvar Ellipta are carefully evaluated and any necessary action taken to protect patients. Relvar Ellipta received a marketing authorisation valid throughout the EU on 13 November 2013.

Who should take Relvar Ellipta?

• patients already adequately controlled on both inhaled corticosteroid and long-acting beta 2 -agonist. Relvar Ellipta is indicated for the symptomatic treatment of adults with COPD with a FEV 1 <70% predicted normal (post-bronchodilator) with an exacerbation history despite regular bronchodilator therapy.

What is Relvar Ellipta?

1. What Relvar Ellipta is and what it is used for Relvar Ellipta contains two active substances: fluticasone furoate and vilanterol. Two different strengths of Relvar Ellipta are available: fluticasone furoate 92 micrograms/vilanterol 22 micrograms and fluticasone furoate 184 micrograms/vilanterol 22 micrograms.

Should I read the patient information leaflet before taking Relvar Ellipta?

Remember to always read the Patient information leaflet before taking Relvar Ellipta. This page is specifically for patients who have been prescribed Relvar Ellipta. If you are not a patient please return to the public website. How it works, what’s in it, how often to take it and other questions about Relvar Ellipta

How effective is Relvar Ellipta?

A fourth study in 1,522 patients showed that Relvar Ellipta was as effective as another medicine containing a corticosteroid (fluticasone propionate) and a long-acting beta-2 agonist (salmeterol). These patients were already well controlled with the comparator medicine and Relvar Ellipta treatment was able to maintain their FEV1.